The DOI matches its Crossref record; the references it cites are not checked yet.
ATF4 alleviates doxorubicin-induced cardiomyopathy through H 2 S-mediated antioxidation
Abstract
Background: Doxorubicin (DOX) remains a cornerstone in the treatment of various cancers. However, its clinical utilization is significantly hampered by dose-dependent cardiotoxicity. The generation of reactive oxygen species (ROS) constitutes the central component of the pathogenesis of DOX-induced cardiotoxicity. Activating transcription factor 4 (ATF4) has been demonstrated to exert a cardioprotective effect and augment cardiac antioxidative capacity in settings of heart failure. However, the role of ATF4 in DOX-induced cardiomyopathy (DIC) remains unknown. Methods: To explore the role of ATF4 in DOX-induced cardiomyopathy, cardiac-specific ATF4 conditional heterozygous mice and AAV9 mediated ATF4 overexpression mouse models were utilized. Cardiac function was assessed by echocardiography. The upstream regulator and downstream mediator of ATF4 were evaluated using RNA-seq analysis and further verified using ChIP assay and luciferase reporter assay. Results: We found a substantial decrease in ATF4 expression levels in the heart of DIC mice. ATF4 +/- mice exhibited a higher degree of susceptibility to DOX-induced cardiotoxicity in comparison with ATF4 flox/flox mice, as evidenced by the manifestation of more severe cardiac dysfunction and a significantly earlier mortality rate. In contrast, cardiacc-specific overexpression ATF4 by AAV9 confers robust cardioprotection against DOX-induced cardiomyopathy. Mechanistically, we identified the upstream regulator of ATF4 as KLF16, which was significantly suppressed during DOX treatment. Further, the decrease of ATF4 led to a reduction in cystathionine γ-lyase (CSE) transcription and hydrogen sulfide (H 2 S) production in the context of DOX-induced cardiotoxicity. ChIP and luciferase reporter assays revealed that ATF4 functioned as the transcription factor of the CSE gene, which is a key enzyme in the synthesis of H 2 S to counteract oxidative stress. Consistently, ROS scavengers or H 2 S donors was shown to mitigate the consequences of ATF4 deficiency. In contrast, the ectopic expression of ATF4 mitigated oxidative stress and apoptosis in DOX-induced cardiotoxicity, both in vivo and in vitro . Conclusions: Our study revealed a novel function of ATF4 in counteracting oxidative stress in DOX cardiotoxicity by promoting the transcription of CSE. ATF4 may represent a promising therapeutic target for the treatment of DOX-induced cardiomyopathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists haven’t been fetched yet
Research works printed but not linked: 41
- 2023, Hydrogen sulfide alleviates mitochondrial damage and ferroptosis by regulating OPA3-NFS1 axis in doxorubicin-induced cardiotoxicity, Cell Signal, 107, 110655, 10.1016/j.cellsig.2023.110655 · DOI
- 10.1093/eurheartj/ehw211 · DOI · Paper page
- 2024, Molecular Mechanisms and Therapeutic Targeting of Ferroptosis in Doxorubicin-Induced Cardiotoxicity, JACC Basic Transl Sci, 9, 811, 10.1016/j.jacbts.2023.10.009 · DOI
- 2023, Mitochondrial quality control mechanisms as therapeutic targets in doxorubicin-induced cardiotoxicity, Trends Pharmacol Sci, 44, 34, 10.1016/j.tips.2022.10.003 · DOI · Paper page
- 10.1016/j.apsb.2024.03.015 · DOI
- 2021, Loss of TRIM21 alleviates cardiotoxicity by suppressing ferroptosis induced by the chemotherapeutic agent doxorubicin, EBioMedicine, 69, 103456, 10.1016/j.ebiom.2021.103456 · DOI
- 2025, Mitochondrial Amount Determines Doxorubicin-Induced Cardiotoxicity in Cardiomyocytes, Adv Sci (Weinh), 12, e2412017, 10.1002/advs.202412017 · DOI
- 2023, Evaluation of Senescence and Its Prevention in Doxorubicin-Induced Cardiotoxicity Using Dynamic Engineered Heart Tissues, JACC CardioOncol, 5, 298, 10.1016/j.jaccao.2023.03.012 · DOI
- 2024, Novel PLGA-based nanoformulation decreases doxorubicin-induced cardiotoxicity, Nanoscale, 16, 9412, 10.1039/D3NR06269D · DOI
- 2023, Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer, J Clin Oncol, 41, 2248, 10.1200/JCO.22.02423 · DOI
- 10.1038/s41418-021-00889-7 · DOI
- 10.1016/j.jbc.2024.107151 · DOI
- Hartwick Bjorkman , S. and R . Oliveira Pereira , The Interplay Between Mitochondrial Reactive Oxygen Species, Endoplasmic Reticulum Stress, and Nrf2 Signaling in Cardiometabolic Health, Antioxid Redox Signal. 35 (4) (2021) 252-269. https://www.ncbi.nlm.nih.gov/pubmed/33599550. · DOI
- 10.1161/CIRCRESAHA.122.321050 · DOI
- 2019, Spliced X-box Binding Protein 1 Stimulates Adaptive Growth Through Activation of mTOR, Circulation, 140, 566, 10.1161/CIRCULATIONAHA.118.038924 · DOI
- 2022, Serine biosynthesis as a novel therapeutic target for dilated cardiomyopathy, Eur Heart J, 43, 3477, 10.1093/eurheartj/ehac305 · DOI
- 2024, Fibroblast growth factor 21 improves diabetic cardiomyopathy by inhibiting ferroptosis via ferritin pathway, Cardiovasc Diabetol, 23, 394, 10.1186/s12933-024-02469-8 · DOI
- 2023, Reduced Mitochondrial Protein Translation Promotes Cardiomyocyte Proliferation and Heart Regeneration, Circulation, 148, 1887, 10.1161/CIRCULATIONAHA.122.061192 · DOI
- 10.1038/s41467-021-24215-4 · DOI · Paper page
- 2024, Hyperactivation of ATF4/TGF-beta1 signaling contributes to the progressive cardiac fibrosis in Arrhythmogenic cardiomyopathy caused by DSG2 Variant, BMC Med, 22, 361, 10.1186/s12916-024-03593-8 · DOI
- 2021, Dapagliflozin suppresses ER stress and protects doxorubicin-induced cardiotoxicity in breast cancer patients, Arch Toxicol, 95, 659, 10.1007/s00204-020-02951-8 · DOI
- 2022, PRMT1 suppresses doxorubicin-induced cardiotoxicity by inhibiting endoplasmic reticulum stress, Cell Signal, 98, 110412, 10.1016/j.cellsig.2022.110412 · DOI
- 10.1161/CIRCRESAHA.119.314681 · DOI · Paper page
- 10.1038/s41568-020-00312-2 · DOI · Paper page
- 10.1080/15548627.2020.1827780;WGROUP:STRING:PUBLICATION · doi:10.1080/15548627.2020.1827780;wgroup:string:publication
- 2025, The mitochondrial integrated stress response: A novel approach to anti-aging and pro-longevity, Ageing Res Rev, 103, 102603, 10.1016/j.arr.2024.102603 · DOI
- 2017, SP and KLF Transcription Factors in Digestive Physiology and Diseases, Gastroenterology, 152, 1845, 10.1053/j.gastro.2017.03.035 · DOI
- 10.1158/1541-7786.MCR-18-0399 · DOI
- 2020, High expression of Kruppel-like factor 5 is associated with poor prognosis in patients with colorectal cancer, Cancer Sci, 111, 2078, 10.1111/cas.14411 · DOI
- 2020, KLF16 Affects the MYC Signature and Tumor Growth in Prostate Cancer, Onco Targets Ther, 13, 1303, 10.2147/OTT.S233495 · DOI
- 2020, PRKD3 promotes malignant progression of OSCC by downregulating KLF16 expression, Eur Rev Med Pharmacol Sci, 24, 12709
- 10.1136/gutjnl-2020-321774 · DOI
- 10.1016/j.niox.2014.01.002 · DOI · Paper page
- 2022, Protein S-sulfhydration: Unraveling the prospective of hydrogen sulfide in the brain, vasculature and neurological manifestations, Ageing Res Rev, 76, 101579, 10.1016/j.arr.2022.101579 · DOI
- 10.1096/fj.201901304R · DOI · Paper page
- 10.1161/CIRCULATIONAHA.113.002208 · DOI · Paper page
- 10.1126/science.1162667 · DOI · Paper page
- 10.1016/J.NIOX.2023.05.002 · DOI
- 2016, Gp130-mediated STAT3 activation by S-propargyl-cysteine, an endogenous hydrogen sulfide initiator, prevents doxorubicin-induced cardiotoxicity, Cell Death Dis, 7, e2339, 10.1038/cddis.2016.209 · DOI
- Nie, L. , M. Liu , J. Chen , Q. Wu , Y. Li , J. Yi , X. Zheng , J. Zhang , C. Chu , and J. Yang , Hydrogen sulfide ameliorates doxorubicin-induced myocardial fibrosis in rats via the PI3K/AKT/mTOR pathway, Mol Med Rep. 23 (4) (2021). https://www.ncbi.nlm.nih.gov/pubmed/33649809. · DOI
- 2016, H2S-Donating Doxorubicins May Overcome Cardiotoxicity and Multidrug Resistance, J Med Chem, 59, 4881, 10.1021/acs.jmedchem.6b00184 · DOI
Metadata
- Authors
- Xu, S., Shi, Y., Zhao, X., Chen, X., Liu, Y., Zhang, F., Yu, F., Ruan, L., Wang, C., Jiang, X., Wang, X., & Zhang, G.
- Publisher
- openRxiv
- Published
- 2025-09-11
- Cited by
- 0
- Type
- Preprint
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ATF4 alleviates doxorubicin-induced cardiomyopathy through H 2 S-mediated antioxidation. https://app.cochat.ai/papers/10.1101/2025.09.03.674119
- The paper
- Xu, S., Shi, Y., Zhao, X., Chen, X., Liu, Y., Zhang, F., Yu, F., Ruan, L., Wang, C., Jiang, X., Wang, X., & Zhang, G. (2025). ATF4 alleviates doxorubicin-induced cardiomyopathy through H 2 S-mediated antioxidation. https://doi.org/10.1101/2025.09.03.674119
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.